CardiomyopathyPredictors of Cardiac Sarcoidosis Using Commonly Available Cardiac Studies
Section snippets
Methods
The present study was a retrospective, chart review study. After institutional review board approval, we queried our electronic medical record for “International Classification of Diseases, 9th revisions” codes related to sarcoidosis in patients aged ≥18 years who had undergone cMRI and FDG-cPET from January 2008 through July 2010. The subjects were only included in the present study if they had met the American Thoracic Society/European Respiratory Society diagnostic criteria for sarcoidosis.1
Results
We identified 126 patients who had undergone at least cMRI and/or FDG-cPET and 70 who had undergone both studies. The baseline demographics are listed in Table 3. Our cohort was predominantly white, with a mean age of 55 years, and 60% were women. Of the 70 patients who had undergone both cMRI and FDG-cPET, 41 (59%) were identified as having ≥1 positive imaging test (Table 3). To test our CS imaging scoring system, each subject's score was compared with their imaging results. The scoring system
Discussion
Our results have suggested that a scoring system composed of commonly available screening tools is a reasonable method to predict which patients are likely to have positive findings using FDG-cPET or cMRI for diagnosing CS. The scoring system positivity was driven more by cMRI than FDG-cPET. Our a priori scoring system has shown promise for predicting CS (defined by positive imaging findings) without the routine use of expensive imaging tests. However, it still needs additional refinement and
Acknowledgment
Data used for this study were downloaded from the National Jewish Health Research Database (https://rdb.njc.org/sec/r2prd/ep/home.cfm), supported by National Jewish Health.
References (29)
- et al.
Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing
Chest
(2008) - et al.
Sarcoidosis mortality in the United States, 1979–1991: an analysis of multiple-cause mortality data
Am J Med
(1996) Cardiac sarcoidosis: there is no instant replay
Chest
(2005)- et al.
Myocardial sarcoidosis
Chest
(1993) - et al.
Cardiac sarcoidosis: the value of magnetic resonance imaging in diagnosis and assessment of response to treatment
Respir Med
(1998) - et al.
Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow up study
Chest
(2002) - et al.
Management of cardiac sarcoidosis in the United States: a Delphi study
Chest
(2012) - et al.
Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis
J Nucl Cardiol
(2009) - et al.
Two-dimensional echocardiographic findings in systemic sarcoidosis
Am J Cardiol
(1989) - et al.
Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis
Chest
(1994)
Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis
J Am Coll Cardiol
Evaluation for cardiac sarcoidosis—uncertainty despite contemporary multi-modality imaging
J Card Failure
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999
Am J Respir Crit Care Med
Cardiac sarcoidosis
Heart
Cited by (50)
ACR Appropriateness Criteria® Nonischemic Myocardial Disease with Clinical Manifestations (Ischemic Cardiomyopathy Already Excluded)
2021, Journal of the American College of RadiologyCitation Excerpt :Low T2 value and short T1 in >50% of myocardium T1 scout image are also poor prognostic factors [2]. MRI has sensitivity of 75% to 100% and specificity of 75% to 77% in the diagnosis of cardiac sarcoidosis [54,68,69]. In the acute stage, MRI shows wall thickening, high T2 signal (due to edema), high native T1 and T2 values, RWMA, and LGE.
Optimizing routine screening for cardiac sarcoidosis through use of commonly available studies
2021, Respiratory MedicineCitation Excerpt :Their conclusion was the presence of one abnormal test had a 100% sensitivity and 87% specificity for CS, using an abnormal FDG-PET or CMR as the diagnostic standard [18]. A retrospective trial of 70 patients by Freeman et al., in 2013 found a range of sensitivities for the individual tests ranging from 40 to 80% with ARM having the highest sensitivity [19]. In 2016, the HRS consensus statement recommended obtaining a cardiologic review of systems, EKG, and TTE with further testing for any abnormal result.
Sarcoidosis
2021, Encyclopedia of Respiratory Medicine, Second EditionChallenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review
2020, Journal of the American College of CardiologyCardiac Sarcoidosis: Remembering the Forgotten Right Ventricle
2020, JACC: Cardiovascular ImagingEchocardiography in Infiltrative Cardiomyopathy
2019, Heart Lung and CirculationCitation Excerpt :Generally standard echocardiography abnormalities are variable and non-specific. Any abnormalities considered cardiac sarcoid-specific detected on echocardiography have been shown to have 62% sensitivity but only 29% specificity for confirmed cardiac sarcoidosis [44]. Only 25% of patients with cardiovascular magnetic resonance (CMR) or 18F-FDG-PET evidence of cardiac sarcoid had ‘typical’ abnormalities in their echocardiogram [38].
See page 284 for disclosure information.